Dual-Threat Dilemma: Medical Device Companies Navigate Patent and FDA Approval Processes

Repercussions of the patent application disclosure process for medical device companies intending to profit from their inventions has long been under-discussed. Industries across the board have the shared experience of navigating two agency approvals, one from the U.S. Food and Drug Administration (FDA), and another from the U.S. Patent and Trade Office. Recently, a fascinating…

Read More

Federal Circuit Revisits Design Patent Obviousness Doctrine: Implications for Intellectual Property Law

On June 30, 2023, the U.S. Court of Appeals for the Federal Circuit declared it would rehear the compelling case of LKQ Corp. v. GM Global Tech Operations en banc. The announcement has sparked anticipation among legal professionals around the world. The full court’s intention to reevaluate the existing doctrine on design patent obviousness, a…

Read More

Navigating Patent Eligibility: Alice Two-Step and Section 112 Enablement Waltz in Intellectual Property Law

The US Court of Appeals for the Federal Circuit recently affirmed the dismissal of a lawsuit related to subject matter eligibility, thrusting the legal community into discussions about intellectual property law interpretation. The lawsuit in question, Realtime Data LLC v. Array Networks Inc., Case No. 2021-2251, was thrown out based on an Alice two-step analysis…

Read More

Federal Circuit Ruling Clarifies Distinction for Original Patent and Written Description Requirements

In a recent precedential opinion, the U.S. Court of Appeals for the Federal Circuit clarified the original patent requirement based on Title 35 of the U.S. Code, Section 251, which applies to reissue applications. The decision, named ‘In re: Float’N’Grill LLC’, differentiates the original patent requirement from the written description requirement, further explaining what is…

Read More

AstraZeneca’s Calquence Secures $2B Future as PTAB Rejects Patent Review

AstraZeneca’s cancer drug Calquence, has weathered a significant challenge by dodging a review by the Patent and Trial Appeal Board (PTAB). Calquence, a pharmaceutical drug that has accounted for more than $2 billion in sales for AstraZeneca the previous year, is clearly a high-valued asset for the international pharmaceutical company. The legal confrontation had commenced…

Read More

Supreme Court Urged to Dismiss Review on Invalidated Blood Test Patents: Debating Medical Innovation’s Eligibility

Medical testing companies, Natera Inc. and Eurofins Viracor LLC, recently urged the U.S. Supreme Court to refrain from reviewing the invalidation of Stanford University and CareDx patents for their innovatory blood test. The blood test, crucial for detecting organ rejection, had its patents invalidated as they were deemed to cover only natural phenomena. Law360 reported…

Read More

Federal Circuit Dismisses WeatherTech Rehearing Petition, Upholding Patent Invalidations

The Federal Circuit has dismissed a petition for rehearing in the case involving WeatherTech. The court had previously invalidated two patents linked to the WeatherTech brand of floor mat. Interestingly, these patents were originally upheld at the Patent Trial and Appeal Board. The dismissal means that the Federal Circuit’s previous decision to invalidate these patents…

Read More

Intuitive Surgical and Auris Settle High-Stakes Robotic Surgery Patent Dispute

In a long-winded patent battle among industry giants Intuitive Surgical and Johnson & Johnson subsidiary Auris, there has finally been a resolution. The two entities have agreed to settle a nearly five-year lawsuit regarding accusations of infringement on various surgical robot patents. The agreement thereby concludes a span of protracted litigation that began back in…

Read More

Federal Circuit Ruling Sets Precedent on Intent to Infringe in Patent-Related Cases

In a recently published article on JD Supra, the U.S. Federal Circuit is closely monitoring legal developments around patent law. Specifically, the question of whether pending, non-final litigation or Inter Partes Review (IPR) processes can negate intent to infringe if there’s already substantive evidence supporting such intentions. The focal point of this legal discussion is…

Read More

PTAB Denies Mercedes Benz USA’s Institution Petition in High-Stakes Patent Dispute with Westport Fuel Systems

In a noteworthy instance of patent law, the Patent Trial and Appeal Board (PTAB) has denied an institution petition from Mercedes Benz USA, disputing the filing date of a challenged patent held by Westport Fuel Systems Canada Inc. The case in question, Mercedes-Benz USA, LLC v. Westport Fuel Systems Canada Inc, Case IPR2023-00351, unfolded earlier…

Read More

USPTO Unveils 2022 Updates to Trademark Datasets, Boosting Transparency and Market Insights

In light of recent developments, we examine the July 11 announcement by the United States Patent and Trademark Office (USPTO). The Office of the Chief Economist publicized the 2022 updates to its Trademark Case Files Dataset and Trademark Assignment Dataset. An evaluation of these updates shows an ongoing investment by the USPTO in improved transparency…

Read More